Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Zachary BessetteMuscle Invasive Urothelial Carcinoma | December 6, 2022
DLRS-based MLP was clinical useful in distinguishing non-muscle-invasive bladder cancer from muscle-invasive bladder cancer.
Read More
Leah LawrenceMuscle Invasive Urothelial Carcinoma | November 28, 2022
MRE11 “has been identified as a candidate predictive biomarker," as higher levels are associated with more ...
Emily MenendezMuscle Invasive Urothelial Carcinoma | October 31, 2022
At a 36-month follow-up, the EFS and OS rates were 74.4% and 83.8% in the ITT group, and 92% of patients underwent RC.
Leah LawrenceMuscle Invasive Urothelial Carcinoma | October 31, 2022
ddMVACx6 was demonstrated to improve progression-free survival compared with GCx4 for muscle-invasive disease.
Leah LawrenceMuscle Invasive Urothelial Carcinoma | October 25, 2022
The data, published in Clinical Genitourinary Cancer, showed a lack of benefit of adjuvant ICIs across multiple subgroups.
Cecilia BrownMuscle Invasive Urothelial Carcinoma | August 15, 2022
A trial utilized atezolizumab, a monoclonal antibody directed at the PD-L1 protein, in patients with MIBC.
Emily MenendezMuscle Invasive Urothelial Carcinoma | May 25, 2022
Clinical trial results showed that immunotherapy drug nivolumab helps reduce cancer recurrence in bladder cancer patients.
GU Oncology Now EditorsMuscle Invasive Urothelial Carcinoma | May 24, 2022
...
GU Oncology Now EditorsASCO GU Symposium 2022 | February 21, 2022
Trial oncolytic measles virus encoding thyroidal sodium iodide symporter treatment may be effective in patients with UC.
Advertisement
Advertisement